|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.80 BDT | +0.26% |
|
+1.41% | +9.75% |
Company Valuation: Beacon Pharmaceuticals PLC
Data adjusted to current consolidation scope
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 14,022 | 28,552 | 59,667 | 56,595 | 35,528 | 24,463 |
| Change | - | 103.62% | 108.98% | -5.15% | -37.22% | -31.14% |
| Enterprise Value (EV) 1 | 15,590 | 30,705 | 62,950 | 63,573 | 45,525 | 34,426 |
| Change | - | 96.96% | 105.01% | 0.99% | -28.39% | -24.38% |
| P/E | 36.8x | 33.1x | 63.8x | 111x | 68.2x | 25.8x |
| PBR | 3.03x | 5.33x | 10x | 9.52x | 5.83x | 3.67x |
| PEG | - | 0x | 7.66x | -2.4x | 31.14x | 0.3x |
| Capitalization / Revenue | 2.51x | 4.01x | 7.44x | 6.65x | 3.32x | 1.95x |
| EV / Revenue | 2.79x | 4.31x | 7.85x | 7.47x | 4.25x | 2.74x |
| EV / EBITDA | 18.5x | 17.6x | 30.6x | 42.8x | 19.3x | 11.6x |
| EV / EBIT | 46.8x | 22.5x | 38.9x | 65.7x | 24.9x | 14.7x |
| EV / FCF | -67.9x | -54.6x | -54.9x | -18.2x | -14.7x | -3,997x |
| FCF Yield | -1.47% | -1.83% | -1.82% | -5.5% | -6.81% | -0.03% |
| Dividend per Share 2 | - | 1.5 | 1.6 | 1.6 | 2 | 2.1 |
| Rate of return | - | 1.21% | 0.62% | 0.65% | 1.3% | 1.98% |
| EPS 2 | 1.648 | 3.737 | 4.048 | 2.207 | 2.255 | 4.097 |
| Distribution rate | - | 40.1% | 39.5% | 72.5% | 88.7% | 51.3% |
| Net sales 1 | 5,591 | 7,121 | 8,023 | 8,510 | 10,702 | 12,543 |
| EBITDA 1 | 844.5 | 1,747 | 2,057 | 1,487 | 2,356 | 2,966 |
| EBIT 1 | 333.5 | 1,362 | 1,617 | 967.7 | 1,828 | 2,334 |
| Net income 1 | 380.7 | 863.2 | 935 | 509.8 | 521 | 946.5 |
| Net Debt 1 | 1,568 | 2,153 | 3,282 | 6,978 | 9,997 | 9,963 |
| Reference price 2 | 60.70 | 123.60 | 258.30 | 245.00 | 153.80 | 105.90 |
| Nbr of stocks (in thousands) | 231,000 | 231,000 | 231,000 | 231,000 | 231,000 | 231,000 |
| Announcement Date | 12/20/21 | 12/20/21 | 11/22/22 | 12/5/23 | 12/10/24 | 4/3/26 |
1BDT in Million2BDT
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 215M | ||
| 34.43x | 12.54x | 25.95x | 0.57% | 1,054B | ||
| 27.51x | 6.31x | 17.15x | 2.07% | 621B | ||
| 30.73x | 7.36x | 15.07x | 2.77% | 438B | ||
| 17.67x | 4.38x | 10.82x | 3.03% | 325B | ||
| 21.42x | 5.5x | 13.31x | 2.87% | 281B | ||
| 21.07x | 4.44x | 12.4x | 1.98% | 262B | ||
| 14.26x | 5.33x | 10.96x | 3.5% | 219B | ||
| 23.64x | 6.27x | 11.07x | 2.8% | 195B | ||
| -47.34x | 5.67x | 31.3x | 2.47% | 163B | ||
| Average | 15.93x | 6.42x | 16.45x | 2.45% | 355.64B | |
| Weighted average by Cap. | 23.64x | 7.82x | 18.21x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BEACONPHAR Stock
- Valuation Beacon Pharmaceuticals PLC
Select your edition
All financial news and data tailored to specific country editions
















